We discuss our ongoing randomized study of IGM-8444 in combination with FOLFIRI + bevacizumab compared to FOLFIRI + bevacizumab alone in second line metastatic colorectal cancer (mCRC) (NCT04553692).Methods: This study is a Phase 1b, multicenter, randomized, open-label clinical trial of IGM-...